The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

advancedcancertherapeutics.com

Founded Year

2007

Stage

Unattributed VC | Alive

Total Raised

$10.64M

Last Raised

$10M | 12 yrs ago

About Advanced Cancer Therapeutics

Advanced Cancer Therapeutics engages in the discovery, development, manufacture, and commercialization of cancer therapeutics.

Advanced Cancer Therapeutics Headquarters Location

300 East Market Street Suite 280

Louisville, Kentucky, 40202,

United States

502-589-6404

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Advanced Cancer Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Advanced Cancer Therapeutics is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

838 items

Advanced Cancer Therapeutics Patents

Advanced Cancer Therapeutics has filed 7 patents.

The 3 most popular patent topics include:

  • Alkene derivatives
  • Clusters of differentiation
  • Cytokines
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/9/2017

7/3/2018

Trifluoromethyl compounds, Glycolysis, Experimental cancer drugs, Monoclonal antibodies, EC 2.7.1

Grant

Application Date

5/9/2017

Grant Date

7/3/2018

Title

Related Topics

Trifluoromethyl compounds, Glycolysis, Experimental cancer drugs, Monoclonal antibodies, EC 2.7.1

Status

Grant

Latest Advanced Cancer Therapeutics News

Qualigen obtains exclusive license to novel cancer drug technology from Advanced Cancer Therapeutics

Dec 18, 2018

0 Message : *Required fields CARLSBAD, Calif., Dec. 18, 2018 /PRNewswire/ -- Qualigen, Inc., and Advanced Cancer Therapeutics, LLC (ACT) today announced that Qualigen has licensed certain ACT patents, intellectual property and know-how associated with the antiproliferative activity of G-rich oligonucleotides ACT-GRO-777 (also known as AS1411) and methods of using these to bind to nucleolin, a protein that is present on the surface of tumor cells. AS1411 is a novel aptamer-based anticancer technology and a key component of Qualigen's anti-nucleolin agent-conjugated nanoparticle drug (AS1411-GNP) that can be used to treat virtually any type of cancer. The AS1411 aptamer has been tested as a drug in over 100 patients and is well tolerated with no evidence of severe side effects, with at least 7 patients having long-lasting clinical responses, where their cancers either disappeared or shrank substantially. Under this License Agreement, Qualigen will obtain the exclusive rights to develop and commercialize ACT-GRO-777/AS1411 and related compounds. In return, ACT will receive potential equity in Qualigen, along with cash payments on the achievement of certain milestones and royalties on future drug sales. "We are delighted to add ACT-GRO-777/AS1411 to our portfolio of anticancer drug technologies. This is a unique opportunity to continue development of a compound that has already undergone extensive preclinical characterization and shown promise in prior clinical studies. We believe that Qualigen's new AS1411-GNP formulation will lead to a significant improvement in potency and absorption in humans, enabling the drug to fulfill the promise seen in the earlier studies," noted Michael S. Poirier, Chairman, CEO and President of Qualigen. "We are excited to work with Qualigen on the product development of our aptamer-based drug to fight cancer," said Randall Riggs, Board Member of ACT. About Qualigen, Inc. Qualigen, Inc. is a medical device company focused on the development, production and commercialization of innovative medical technologies, including its flagship FastPack® point-of-care immunoassay system and novel therapeutic technologies for treatment of cancers and infectious diseases. For more information, visit www.qualigeninc.com . View original content: http://www.prnewswire.com/news-releases/qualigen-obtains-exclusive-license-to-novel-cancer-drug-technology-from-advanced-cancer-therapeutics-300768398.html

  • When was Advanced Cancer Therapeutics founded?

    Advanced Cancer Therapeutics was founded in 2007.

  • Where is Advanced Cancer Therapeutics's headquarters?

    Advanced Cancer Therapeutics's headquarters is located at 300 East Market Street, Louisville.

  • What is Advanced Cancer Therapeutics's latest funding round?

    Advanced Cancer Therapeutics's latest funding round is Unattributed VC.

  • How much did Advanced Cancer Therapeutics raise?

    Advanced Cancer Therapeutics raised a total of $10.64M.

  • Who are the investors of Advanced Cancer Therapeutics?

    Investors of Advanced Cancer Therapeutics include Commonwealth Seed Capital, Kentucky Cabinet for Economic Development and Yearling Fund.

  • Who are Advanced Cancer Therapeutics's competitors?

    Competitors of Advanced Cancer Therapeutics include Echelon Biosciences, IRX Therapeutics, 2cureX, Terpenoid Therapeutics, EpiTherapeutics and 12 more.

You May Also Like

W
Welichem Biotech

Welichem Biotech Inc. ("Welichem", TSX-V: WBI) is engaged in the discovery and development of small molecule therapeutics. Using its Symbiochem technology platform, the Company has developed a robust pipeline of patent-protected compounds that target autoimmune/inflammatory diseases and cancers. Welichem's lead drug candidate, WBI-1001, targets autoimmune/inflammatory skin disorders, such as psoriasis and eczema. A phase I clinical trial of WBI-1001, done in Montreal, in patients with psoriasis has shown a very good safety profile and promising efficacy. As well, the application of WBI-1001 cream against atopic dermatitis (a type of eczema) in a phase IIa clinical trial also has been completed in Canada, with the final report pending in the third quarter of 2008. Welichem plans to all the necessary Phase II Clinical Trials against psoriasis and eczema in the near future. In the company's pipeline, WBI-1001 related compounds are being evaluated also for their therapeutic potential against other autoimmune diseases such as, inflammatory bowel disease and rheumatoid arthritis. Welichem's other lead drug candidate, WBI-2100, selectively targets certain types of hard-to-treat cancerous tumours. This is achieved in part through inhibition of angiogenesis and metastasis. Animal tests have shown that WBI-2100 is effective as a monotherapy and also in increasing the effectiveness of several commonly used chemotherapeutic products. The uniqueness of this small molecule cancer chemotherapeutic is that in pre-clinical studies it increases the number of neutrophils in the peripheral blood. The boosting of neutrophils in animal studies in the presence of the cancer therapeutic, cyclophosphamide, supports its potential therapeutic application for chemotherapy induced neutropenia. With its proven Symbiochem; technology platform, Welichem will advance its pipeline of drug candidates at a rate and time commensurate with resources and target need, and is in a strong position to contribute effectively to productive drug discovery and development partnerships.

Sentinel Oncology Logo
Sentinel Oncology

Sentinel Oncology is a small molecule drug discovery company focusing on the discovery and development of new chemical entities for the treatment of cancer.

I
IITRI Drug Discovery Division

IIT Research Institute (IITRI) is a contract research organization (CRO) that aims to provide non-clinical toxicology and other drug development services to government and industry. IITRI offers particular expertise in oncologics drug development, inhalation toxicology and technology, carcinogenesis and cancer prevention, and biodefense. IITRI's Drug Discovery Division is a research-based group whose focus is the design and synthesis of new small molecule therapeutics for cancer and infectious disease.

T
Terpenoid Therapeutics

Terpenoid Therapeutics is a drug discovery and development company focused on treatments for cancer. The company are developing a portfolio of small molecule- based compounds primarily for treatment of prostate, brease, brain, lung and colon cancers.

M
Medicor Biosciences

Medicor Biosciences, founded in 2006 is a development-stage company focused on drug discovery for combating cancer. The founding scientists are leaders in a class of anti-hormone drugs that are designed to block the relaxin hormone cellular signaling pathways in a number of different cancer types. Using the company's Relaxofen technology platform, therapeutic candidates are generated by engineering the natural relaxin peptide to display antagonistic properties. Through pre-clinical development and clinical trials, Medicor Biosciences plans to develop and potentially license the technology so that the therapeutics can be available for cancer patients as an anti-hormone therapy to impair the growth and spread of the disease.

A
AndroScience

AndroScience intends to use its expertise in natural product chemistry to discover compounds that target at different stages of the androgen activation pathway, and to develop lead compounds into new medicines for acne, androgenetic alopecia, wound healing, benign prostatic hyperplasia, prostate cancer and for other androgen or androgen receptor-related disorders.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.